Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes ; volume:17 ; number:1 ; day:3 ; month:5 ; year:2015 ; pages:1-14 ; date:12.2015
Breast cancer research ; 17, Heft 1 (3.5.2015), 1-14, 12.2015
- Keyword
-
Krebs
Onkologie
- Creator
-
Kim, Hee Jeong
- Contributor
-
Kwon, Hyunwook
Lee, Jong Won
Kim, Hwa Jung
Lee, Sae Byul
Park, Hee Sung
Sohn, Guiyun
Lee, Yura
Koh, Beom Seok
Yu, Jong Han
Son, Byung Ho
Ahn, Sei Hyun
SpringerLink (Online service)
- DOI
-
10.1186/s13058-015-0574-3
- URN
-
urn:nbn:de:1111-201702265237
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Hee Jeong
- Kwon, Hyunwook
- Lee, Jong Won
- Kim, Hwa Jung
- Lee, Sae Byul
- Park, Hee Sung
- Sohn, Guiyun
- Lee, Yura
- Koh, Beom Seok
- Yu, Jong Han
- Son, Byung Ho
- Ahn, Sei Hyun
- SpringerLink (Online service)
Other Objects (12)
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer